Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:COGT NASDAQ:IMVT NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.600.0%$35.01$10.95▼$40.26$5.91B1.132.25 million shs73,993 shsCOGTCogent Biosciences$33.71-1.4%$35.90$4.55▼$43.73$5.76B0.372.01 million shs241,834 shsIMVTImmunovant$28.38-2.0%$26.30$13.71▼$30.16$5.77B0.71.42 million shs97,043 shsPGENPrecigen$4.47-2.9%$3.83$1.28▼$5.47$1.59B1.074.22 million shs863,114 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.05%-0.03%+0.03%+60.26%+222.74%COGTCogent Biosciences-0.29%-1.72%-6.30%-6.41%+600.61%IMVTImmunovant-0.99%+6.39%+9.08%+12.47%+110.16%PGENPrecigen+10.84%+10.84%+15.87%-6.69%+259.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.600.0%$35.01$10.95▼$40.26$5.91B1.132.25 million shs73,993 shsCOGTCogent Biosciences$33.71-1.4%$35.90$4.55▼$43.73$5.76B0.372.01 million shs241,834 shsIMVTImmunovant$28.38-2.0%$26.30$13.71▼$30.16$5.77B0.71.42 million shs97,043 shsPGENPrecigen$4.47-2.9%$3.83$1.28▼$5.47$1.59B1.074.22 million shs863,114 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.05%-0.03%+0.03%+60.26%+222.74%COGTCogent Biosciences-0.29%-1.72%-6.30%-6.41%+600.61%IMVTImmunovant-0.99%+6.39%+9.08%+12.47%+110.16%PGENPrecigen+10.84%+10.84%+15.87%-6.69%+259.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 2.21Hold$40.702.79% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7329.74% UpsideIMVTImmunovant 2.45Hold$32.4414.31% UpsidePGENPrecigen 2.33Hold$11.00146.36% UpsideCurrent Analyst Ratings BreakdownLatest PGEN, COGT, CNTA, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.005/14/2026PGENPrecigen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026PGENPrecigen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$9.00 ➝ $11.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.004/21/2026PGENPrecigen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$35.00 ➝ $42.004/15/2026IMVTImmunovant The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$29.00 ➝ $32.004/13/2026CNTACentessa Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$38.004/10/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026IMVTImmunovant Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa PharmaceuticalsN/AN/AN/AN/A$3.27 per shareN/ACOGTCogent BiosciencesN/AN/AN/AN/A$3.18 per shareN/AIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/APGENPrecigen$9.68M164.44N/AN/A$0.06 per share74.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%N/ACOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%N/AIMVTImmunovant-$413.84M-$2.69N/AN/AN/AN/A-63.17%-58.01%5/20/2026 (Estimated)PGENPrecigen-$250.64M-$1.34N/A15.95N/A-646.99%956.93%58.04%N/ALatest PGEN, COGT, CNTA, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60N/AN/AN/AN/AN/A5/13/2026Q1 2026PGENPrecigen-$0.03-$0.02+$0.01-$0.02$20.81 million$23.25 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A3/25/2026Q4 2025PGENPrecigen-$0.10-$0.01+$0.09-$0.01$8.29 million$4.57 million2/17/2026Q4 2025COGTCogent Biosciences-$0.51-$0.55-$0.04-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.239.539.53COGTCogent Biosciences0.4115.1415.14IMVTImmunovantN/A15.7415.74PGENPrecigen4.463.092.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%COGTCogent BiosciencesN/AIMVTImmunovant47.08%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals4.09%COGTCogent Biosciences7.29%IMVTImmunovant1.80%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200149.23 million143.13 millionOptionableCOGTCogent Biosciences80170.87 million158.41 millionOptionableIMVTImmunovant120203.53 million199.87 millionOptionablePGENPrecigen190356.51 million188.59 millionOptionablePGEN, COGT, CNTA, and IMVT HeadlinesRecent News About These CompaniesPrecigen (NASDAQ:PGEN) Given New $11.00 Price Target at Citizens JmpMay 15 at 3:41 AM | americanbankingnews.comPrecigen (NASDAQ:PGEN) Stock, Earnings Estimates, EPS, And RevenueMay 14 at 11:37 PM | benzinga.comPrecigen Earnings Call Highlights PAPZIMEOS Launch SurgeMay 14 at 8:30 PM | tipranks.comPrecigen IncMay 14 at 6:36 PM | edition.cnn.comPrecigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...May 14 at 6:36 PM | finance.yahoo.comPrecigen’s lead cancer therapy is fueling a massive stock rally — here’s what Wall Street sees nextMay 14 at 6:36 PM | msn.comPrecigen jumps after Q1 beat as Papzimeos launch momentum takes holdMay 14 at 6:36 PM | msn.comWhy is Precigen stock surging today?May 14 at 8:16 AM | za.investing.comPrecigen anticipates funding through cash flow breakeven by end of 2026 as PAPZIMEOS launch scalesMay 14 at 8:16 AM | seekingalpha.comPrecigen (PGEN) Q1 2026 Earnings TranscriptMay 14 at 8:16 AM | fool.comPrecigen Q1 Earnings Call HighlightsMay 13 at 12:11 AM | marketbeat.comPrecigen, Inc. (PGEN) Q1 2026 Earnings Call TranscriptMay 13 at 11:00 PM | seekingalpha.comPrecigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue EstimatesMay 13 at 6:36 PM | zacks.comPrecigen Reports First Quarter 2026 Financial Results and Business UpdatesMay 13 at 4:05 PM | prnewswire.comPrecigen (PGEN) Expected to Announce Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comPrecigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13May 7, 2026 | prnewswire.comPrecigen (PGEN) to Release Earnings on WednesdayMay 6, 2026 | marketbeat.comPrecigen (NASDAQ:PGEN) Stock Crosses Below 200 Day Moving Average - Here's WhyMay 5, 2026 | marketbeat.comIs Precigen, Inc. (PGEN) A Good Stock To Buy Now?May 3, 2026 | finance.yahoo.comIs Precigen, Inc. (PGEN) A Good Stock To Buy Now?May 3, 2026 | insidermonkey.comPrecigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Hold" by AnalystsApril 26, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePGEN, COGT, CNTA, and IMVT Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$39.60 -0.01 (-0.01%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Cogent Biosciences NASDAQ:COGT$33.70 -0.49 (-1.42%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Immunovant NASDAQ:IMVT$28.38 -0.58 (-1.99%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Precigen NASDAQ:PGEN$4.46 -0.14 (-2.93%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
